FDA approves Novo Nordisk's Rybelsus as first-line treatment option
Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.
by marketwire, translated by daniel pedersen
Novo Nordisk’s Rybelsus (semaglutide), a type 2 diabetes tablet treatment, has been authorized by the US Food and Drug Administration, FDA, as a first-line treatment option.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
All Wegovy dose strengths are back on US market
For subscribers
Novo Nordisk testing weekly diabetes tablet in phase I
For subscribers
